Cognitive Training to Improve Cognitive Function Following Chemotherapy

NCT ID: NCT01013233

Last Updated: 2009-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to improve cognitive dysfunction following chemotherapy, the investigators investigated to see whether a cognitive training for memory and concentration skills can improve cognitive performance in patients following cancer treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients following chemotherapy invited for a cognitive training. Before and after cognitive function will evaluate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

training

Patients in this group start the cognitive training over 6 weeks directly after randomization.

Group Type EXPERIMENTAL

cognitive training

Intervention Type BEHAVIORAL

cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.

control

In this control group begin the training in a cross-over design 7 weeks after randomization.

Group Type PLACEBO_COMPARATOR

control group

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cognitive training

cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.

Intervention Type BEHAVIORAL

control group

no intervention

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

training group controll group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with cancer 6 weeks after chemotherapy

Exclusion Criteria

* patients with neurological or psychiatric disorders
* patients without compliance
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Freie Universität Berlin

OTHER

Sponsor Role collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Charite University, Berlin, Germany

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Niedeggen, PhD

Role: PRINCIPAL_INVESTIGATOR

Freie Universität Berlin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charite Universitätsmedizin Berlin

Berlin, State of Berlin, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Susanne Effenberger, MSc

Role: CONTACT

+49-30-8445-2410

Fernando Dimeo, MD

Role: CONTACT

+49-30-8445-4834

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Susanne Effenberger, MSc

Role: primary

+49-30-8445-2410

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KTST09

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.